TRT Kingdom review

What it is

TRT Kingdom is a hormone-therapy telehealth platform co-founded by bodybuilder Jay Cutler, with Daniel Olivero as chief medical officer and nurse practitioners including Joseph Lacourse and Amber Thomas on staff. Its catalog runs four categories: Hormone Therapy (testosterone cypionate therapy, enclomiphene, HCG, follicle-stimulating hormone, nandrolone decanoate and an oral testosterone derivative for men; testosterone injections alone or with progesterone and estrogen for women), Peptides (empty), Weight Loss (compounded GLP-1 and GLP-1/GIP plus microdosing variants, phentermine, Lipo B, L-carnitine) and Wellness (sermorelin, PT-141, NAD⁺, glutathione, B12, modafinil, sildenafil, tadalafil).

How it works

Asynchronous by default, with lab work required before hormone therapy and a synchronous consultation available if a provider decides one is needed. Its own FAQ describes the model precisely: most wellness treatments can be prescribed through asynchronous review, a licensed medical provider reviews your intake forms and determines eligibility, and providers will consult with you directly if a synchronous visit is required. The lab workflow is stated plainly — Kingdom orders the labs, you get a lab order by email and schedule a draw at a local LabCorp, and the cost is "paid to Kingdom as part of your care", which means billed to you rather than covered by the plan. Naming a chief medical officer and individual nurse practitioners is better disclosure than most of this board offers. What is missing is everything downstream: the compounding pharmacy is described only as an FDA-registered US pharmacy and never named, no state availability list is published, and the empty Peptides category means the navigation itself overstates what is on sale. Product pages are client-rendered, which is why several earlier automated passes on this site returned only customer-review text.

Pricing transparency

Every price on the platform is attached to a plan length, and no product offers a month-to-month option. Testosterone cypionate is $99 a month on a 2.5-month plan, $89 on six months and $79 on twelve. NAD⁺ is $79 a month on a 2.5-month plan. Sermorelin is $233 a month on a three-month plan. On top of that sits a recurring lab fee the site states as $149 every six months, with more frequent testing possible at provider discretion. So the honest first-year figure for testosterone is the plan cost plus two lab fees, not the sticker. That is why we publish no floor on any of its three boards: a per-month number that only exists inside a minimum commitment, with a separate recurring charge outside it, is not a monthly price. The site's "no hidden fees" framing is accurate in the narrow sense that the lab fee is disclosed — but it is disclosed inside an FAQ answer that only renders client-side, not next to the price. Ask what your total first-year outlay is, including labs, before committing to a twelve-month plan.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The site states its compounded GLP-1 and GLP-1/GIP medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality, which is the correct disclosure, and it states that medications are prescribed by a licensed physician and dispensed from an FDA-registered US pharmacy — a facility it does not name. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the catalog spans the whole range. Testosterone replacement has a large randomised safety base and requires ongoing haematocrit, PSA and testosterone monitoring; the required lab work here supports that, though the schedule is provider-discretionary. Enclomiphene has real data on raising testosterone and thinner data on symptoms and long-term safety. Sermorelin acts on a real growth-hormone axis with thin long-term human outcome data. Injected NAD⁺ has no controlled human outcome trials; oral NR and NMN raise a biomarker. Glutathione has essentially no controlled human outcome data. PT-141 is an approved molecule for one narrow indication in premenopausal women, so most prescribing of it is off-label use. Individual results vary.

Pros and watch-outs

The evidence behind what TRT Kingdom prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

• TRT and Hematocrit: Why Testosterone Thickens the Blood, and What to Do About It

  Erythrocytosis is the most common lab change on testosterone therapy — predictable, route-dependent, and manageable with monitoring.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

How TRT Kingdom compares

A few alternatives worth a look, depending on what you’re optimizing for.

• TWTonik Wellness

  People who want named pharmacies and a video visit, and will check stock before planning around a price

  See Tonik Wellness →
• TAThriving Again

  Men who want BPC-157 or ipamorelin named up front and will pin the per-molecule price down at intake

  See Thriving Again →
• VVValhalla Vitality

  People who want several NAD⁺ routes on one menu and will register before comparing prices

  See Valhalla Vitality →